Advertisement

Topics

Prokarium secures $10 million for thermostable vaccine development

05:40 EST 26 Feb 2018 | Manufacturing Chemist

Prokarium, a UK-based synthetic biology company and developer of Vaxonella, an oral, thermostable vaccine delivery platform, announced the completion of a $10 million investment round

Original Article: Prokarium secures $10 million for thermostable vaccine development

NEXT ARTICLE

More From BioPortfolio on "Prokarium secures $10 million for thermostable vaccine development"

Advertisement
Quick Search
Advertisement
Advertisement